Skip to content
For research use only. Not for human or veterinary use. Not a drug, food, or dietary supplement.
AMIRAVOResearch Library
Reference vials: BPC-157, TB-500, GHK-Cu
Combination evidence

GLOW (BPC-157 + TB-500 + GHK-Cu)

Also called GLOW blend, GLOW stack, Glow mix

GLOW is a marketing name for a three-peptide mixture of BPC-157, TB-500 and GHK-Cu, none of which is FDA-approved as a drug. No study of the three-component mixture was found in humans or animals. The only related experiment tested two of the three components in rats and found no additive effect 1.

Not studied together in humans

Components

A pre-mixed product with these contents has its own page: GLOW Blend.

What has been studied

  • No human or animal study of the three-component mixture was found. Searched: PubMed (GHK AND copper AND (thymosin OR BPC); "BPC 157" AND thymosin) and ClinicalTrials.gov, October 2026; the hits were narrative and scoping reviews that discuss the peptides individually.
  • A two-component subset (BPC-157 with TB-500) was compared with each peptide alone in a randomised rat Achilles tendon experiment; the combination conferred no additional effect over either agent alone, and GHK-Cu was not studied 1.

Why the pairing is discussed

Mechanistic reasoning drawn from studies of each component. Theoretical unless a study above tested the pair.

  • Theoretical: BPC-157 was associated with VEGFR2-Akt-eNOS activation and increased vessel density in embryo, cell and rat models 2.
  • Theoretical: thymosin beta-4 and its non-acetylated LKKTETQ fragment were associated with dermal wound repair in diabetic and aged mice 3.
  • Theoretical: GHK is proposed to act as a copper(II) complex; a review reports that in laboratory and animal systems it stimulated collagen and glycosaminoglycan synthesis and modulated metalloproteinases 4. These three lines of component evidence are the reason the mixture is discussed; no study shows they combine.

Concerns and unknowns

  • No study of the mixture exists, so interactions, stability in a shared solution and combined pharmacokinetics are unmeasured; the one two-component animal comparison found no additive effect 1.
  • FDA lists BPC-157 and the thymosin beta-4 fragment LKKTETQ (TB-500) among nominated-but-withdrawn compounding substances that may present significant safety risks, citing possible immunogenicity and impurities; for TB-500 FDA states it has no human exposure data, and for BPC-157 that it has no or limited safety information for the proposed routes. 5
  • FDA lists GHK-Cu for injectable routes among nominated-but-withdrawn compounding substances that may present significant safety risks, citing possible immunogenicity from aggregation and impurities and limited human data 5. Human GHK-Cu data come mainly from small topical cosmetic studies 6.
  • WADA's 2026 Prohibited List names BPC-157 in section S0 (non-approved substances, prohibited at all times) and 'Thymosin-beta-4 and its derivatives e.g. TB-500' in section S2.3 (growth factors and growth factor modulators). 7
  • GHK-Cu is not named on the 2026 WADA list; because section S0 covers any substance with no governmental approval for human therapeutic use, its absence is not clearance 7.

Status of each component

CompoundRegulatory statusEvidenceHalf-life
BPC-157Not approved — research use onlyC—
TB-500Not approved — research use onlyC—
GHK-CuNot approved — research use onlyB—

Frequently asked questions

Has the GLOW mixture been studied?
No study of the three-peptide mixture was found in people or animals. A rat study of two of its components found no additive effect 1.
Why combine three peptides?
Each has separate cell or animal findings related to tissue repair 2 3 4. Whether they act together, interfere with each other or stay stable in one vial has not been tested.
Is GHK-Cu the same as in skin creams?
GHK-Cu is used as a cosmetic ingredient, but FDA notes concerns specific to injectable routes, including immunogenicity and limited human data 5.
Are any GLOW components approved?
None of the three is FDA-approved as a drug 5 6.
What is the athlete status?
BPC-157 (S0) and TB-500 (S2.3) are named on WADA's 2026 list; GHK-Cu is not named, but S0 is open-ended 7.

References

  1. Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: A histopathological and biomechanical study Jt Dis Relat Surg. 2026
  2. Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation J Mol Med (Berl). 2017
  3. Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice Wound Repair Regen. 2003
  4. GHK Peptide as a Natural Modulator of Multiple Cellular Pathways in Skin Regeneration Biomed Res Int. 2015
  5. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks (content current as of 04/22/2026) FDA. 2026
  6. Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance Sports Med. 2026
  7. International Standard: Prohibited List 2026 World Anti-Doping Agency. 2026
All combinations Compare the components side by side